| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00535-012-0648-2 |
| P698 | PubMed publication ID | 22875474 |
| P2093 | author name string | Antonio Gasbarrini | |
| Massimo Montalto | |||
| Antonella Gallo | |||
| Raffaele Landolfi | |||
| P2860 | cites work | Lactobacillus rhamnosus GG exacerbates intestinal ulceration in a model of indomethacin-induced enteropathy | Q79938281 |
| NSAID-induced intestinal damage: are luminal bacteria the therapeutic target? | Q80486645 | ||
| Clinical trial: the effects of a probiotic mixture on non-steroidal anti-inflammatory drug enteropathy - a randomized, double-blind, cross-over, placebo-controlled study | Q84043115 | ||
| Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study | Q84071058 | ||
| The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis | Q84290217 | ||
| Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis | Q84538462 | ||
| Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury: a double-blind, randomized, controlled trial evaluated by capsule endoscopy | Q85161214 | ||
| Probiotics in human medicine | Q24540394 | ||
| Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group | Q28138338 | ||
| Lactobacillus acidophilus protects tight junctions from aspirin damage in HT-29 cells | Q28169032 | ||
| Commensal host-bacterial relationships in the gut | Q28188763 | ||
| Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial | Q28217835 | ||
| Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo | Q28235409 | ||
| Lactobacillus casei prevents impaired barrier function in intestinal epithelial cells | Q28300177 | ||
| Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study | Q29620671 | ||
| Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. | Q30581062 | ||
| Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial | Q33872486 | ||
| Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo | Q34392953 | ||
| Metronidazole reduces intestinal inflammation and blood loss in non-steroidal anti-inflammatory drug induced enteropathy | Q34396108 | ||
| Effect of Lactobacillus ingestion on the gastrointestinal mucosal barrier alterations induced by indometacin in humans | Q34512635 | ||
| Probiotics reduce enterohemorrhagic Escherichia coli O157:H7- and enteropathogenic E. coli O127:H6-induced changes in polarized T84 epithelial cell monolayers by reducing bacterial adhesion and cytoskeletal rearrangements | Q34559453 | ||
| Is non-steroidal anti-inflammaory drug (NSAID) enteropathy clinically more important than NSAID gastropathy? | Q34565398 | ||
| Mechanisms of action of probiotics: recent advances | Q34796044 | ||
| Intestinal permeability in the pathogenesis of NSAID-induced enteropathy | Q34923091 | ||
| Present status and strategy of NSAIDs-induced small bowel injury | Q34990032 | ||
| Heat shock protein 70-dependent protective effect of polaprezinc on acetylsalicylic acid-induced apoptosis of rat intestinal epithelial cells. | Q35522352 | ||
| Microbial flora in NSAID-induced intestinal damage: a role for antibiotics? | Q36404975 | ||
| Intestinal mucosal damage caused by non-steroidal anti-inflammatory drugs: role of bile salts. | Q36744903 | ||
| Capsule endoscopic diagnosis of nonsteroidal antiinflammatory drug-induced enteropathy | Q37370014 | ||
| Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract | Q37708639 | ||
| Adverse effects of drugs on small intestine and colon | Q37708641 | ||
| Probiotic bacteria and intestinal epithelial barrier function | Q37714234 | ||
| Aspirin-induced small bowel injuries and the preventive effect of rebamipide | Q39729089 | ||
| Probiotic Lactobacillus casei strain Shirota prevents indomethacin-induced small intestinal injury: involvement of lactic acid | Q39826904 | ||
| Review: The Biochemical Basis of Non-Steroidal Anti-Inflammatory Drug-Induced Damage to the Gastrointestinal Tract: A Review and a Hypothesis | Q40443772 | ||
| Functional modulation of enterocytes by gram-positive and gram-negative microorganisms | Q40580514 | ||
| Effect of probiotic strains on interleukin 8 production by HT29/19A cells | Q40731692 | ||
| Probiotic bacteria enhance murine and human intestinal epithelial barrier function | Q40783633 | ||
| Resistance of germfree rats to indomethacin-induced intestinal lesions | Q40803813 | ||
| Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. | Q40910814 | ||
| Prevention by lansoprazole, a proton pump inhibitor, of indomethacin -induced small intestinal ulceration in rats through induction of heme oxygenase-1. | Q42976861 | ||
| Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study | Q43871043 | ||
| COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice | Q44021745 | ||
| Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. | Q44295966 | ||
| Role of unbalanced growth of gram-negative bacteria in ileal ulcer formation in rats treated with a nonsteroidal anti-inflammatory drug | Q44786104 | ||
| Visible small-intestinal mucosal injury in chronic NSAID users | Q45220712 | ||
| Prevention of nonsteroidal anti-inflammatory drug-induced small-intestinal injury by prostaglandin: a pilot randomized controlled trial evaluated by capsule endoscopy | Q46108964 | ||
| Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis | Q46143449 | ||
| Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study | Q46257145 | ||
| A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy | Q46485023 | ||
| Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination | Q50119689 | ||
| Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent. | Q50467078 | ||
| Effect of prostaglandin on indomethacin-induced increased intestinal permeability in man. | Q52485977 | ||
| Nonsteroidal anti-inflammatory drug-induced small-bowel lesions identified by double-balloon endoscopy: endoscopic features of the lesions and endoscopic treatments for diaphragm disease | Q57131358 | ||
| VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis | Q59120549 | ||
| Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles | Q59880418 | ||
| The biliary elimination and enterohepatic circulation of ibuprofen in rats | Q68703035 | ||
| Misoprostol reduces indomethacin-induced changes in human small intestinal permeability | Q69179532 | ||
| Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG | Q69911178 | ||
| Effects of metronidazole and misoprostol on indomethacin-induced changes in intestinal permeability | Q70587240 | ||
| Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat | Q71528748 | ||
| Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation | Q71933888 | ||
| A new mechanism for anti-inflammatory actions of proton pump inhibitors--inhibitory effects on neutrophil-endothelial cell interactions | Q73782168 | ||
| P433 | issue | 6 | |
| P921 | main subject | probiotics | Q1816730 |
| P304 | page(s) | 689-697 | |
| P577 | publication date | 2012-08-09 | |
| P1433 | published in | Journal of Gastroenterology | Q15764399 |
| P1476 | title | NSAID enteropathy: could probiotics prevent it? | |
| P478 | volume | 48 |
| Q38809387 | Clinical importance of nonsteroidal anti-inflammatory drug enteropathy: the relevance of tumor necrosis factor as a promising target. |
| Q58715584 | Differential effects of selective and non-selective cyclooxygenase inhibitors on fecal microbiota in adult horses |
| Q38773030 | Gut Microbiota Mediates Protection Against Enteropathy Induced by Indomethacin |
| Q64086122 | Lack of Small Intestinal Dysbiosis Following Long-Term Selective Inhibition of Cyclooxygenase-2 by Rofecoxib in the Rat |
| Q28072437 | Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate |
| Q38707937 | Role of non-steroidal anti-inflammatory drugs on intestinal permeability and nonalcoholic fatty liver disease |
| Q35813554 | The influence of non-steroidal anti-inflammatory drugs on the gut microbiome |
| Q50054146 | The role of gut microbiota in the modulation of drug action: a focus on some clinically significant issues |
| Q35026463 | Understanding and modulating mammalian-microbial communication for improved human health |
Search more.